4Nissen SE,Tuzcu EM,Schoenhagen P,et al. For the REVERSAL Inves-tigators effect of intensive compared with moderate lipid-lowering thera-py on progression ot coronary atherosclerosis a randomized controlledtrial[J]. JAMA,2004,291 :1071.
5Baldari CT,Ghittoni R,Lazzerini PE,et al. T lymphocytes as targets ofstatins : molecular mechanisms and therapeutic perspectives [ J ] . In-flamm Aller Drug Targets ,2007 ,6(1) :3.
6Bell RM,Yellon DM. Atorvastatin administered at the onset of re perfu-sion and independent of lipid lowering protects the myocardium by up-regulating a prosurvival pathway[ J]. J Am Coll Cardiol,2003 ,41(3):508.
7Urbich C,Dembach E,Zeiher AM. Double-edged role of statins in an-giogenesis signaling[ J]. Circ Res,2002 ,90 :737.
8Feldstein CA. Statins as antihypertensives recent patents on cardiovas-cular[ J] . drug discovery ,2008 ,3(2) :92.
10Eto M, Kozai T, Cosentino F, et al. Statin prevets tissue factor expres-sion in human endothelial cells role of Rho/Rho2 kinase and Akt path-ways[ J]. Circulation,2002,105( 15) :1756.
二级参考文献37
1[1]Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J].Circulation,2002,106(25):3143-3142.
2[2]Gotto AM Jr,Whitney E,Stein EA,et al.Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS)[J].Circulation,2000,101(5):477-484.
3[3]Kleemann R,Princen HM,Emeis JJ,et al.Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE-Lei-den transgenic mice:evidence for antiinflammatory effects of rosuvastatin[J].Circulation,2003,108 (11):1368-1374.
4[4]Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on C-reactive protein levels.,the pravastatin inflammation/CRP evaluation (PRINCE):a randomized trial and cohort study[J].JAMA,2001,286(1):64-70.
5[5]Ridker PM,Cannon CP,Morrow D,et al.C-reactive protein levels and outcomes after statin therapy[J].N Engl J Med,2005,352(1):20-28.
7[7]Ridker PM,JUPITER Study Group.Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity Creactive protein:rationale and design of the JUPITER trial[J].Circulation,2003,108(19):2292-2297.
8[8]von Haehling S,Anker SD,Bassenge E.Statins and the role of nitric oxide in chronic heart failure[J].Heart Fail Rev,2003,8(1):99-106.
9[9]Liao JK.Beyond lipid lowering:the role of statins in vascular protection[J].Int J Cardiol,2002,86(1):5-18.
10[10]Laufs U,Gertz K,Huang P,et al.Atorvastatin upregulates type Ⅲ nitric oxide synthase in thromhocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31(10):2442-2449.
4Buja LM.Myocardial ischemia and reperfusion injury[J].Cardiovasc Pathol,2005,14(4):1750-1755.
5Staat P,Rioufol G.Postconditioning the human heart[J].Circulation,2005,112(14):2143-2148.
6Pfaffl MW.A new mathematical model for relative quantification in real-time RT-PCR[J].Nucl Acids Res,2001,29(10):2002-2007.
7Nagata K,Obata K,Odashima M,et al.Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation 0f mitochondrial ATP-sensitive potassium channels and nitrate-like effect[J].J Mol Cell Cardiol,2003,35(12):1505-1512.
8Tsutsumi YM,Yokoyama T.Reactive oxygen species trigger ischemic and pharmacological postconditioning:in vivo and in vitro characterization[J].Life Sci,2007,81(15):1223-1227.
9Piot CA,Padmanaban D,Ur sell PC,et al.Ischemic preconditioning decreases apoptosis in rat hearts in vivo[J].Circ,1997,96(5):1598-1604.
